Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer (SCLC).
“Chemoimmunotherapy is the standard first-line treatment…however, its real-world long-term outcomes associated with patient backgrounds are still unclear,” stated Jun Sugisaka, MD, Sendai Kousei Hospital, Sendai, Miyagi, Japan, and coauthors. “We explored this association using an updated large real-world prospective cohort with a minimum follow-up of 3 years.”
In this prospective cohort study, researchers collected data from 207 patients with extensive-stage SCLC who received carboplatin, etoposide, and atezolizumab. Based on eligibility criteria for a pivotal phase 3 trial, patients were identified as either trial-eligible (n = 132) or trial-ineligible (n = 75). Primary end points included progression-free survival (PFS) and overall survival (OS) probability. A key secondary end point was OS based on trial eligibility status.
At a median follow-up of 42.2 months, the 3-year PFS probability was 6.1% and the 3-year OS probability was 20.9%. The 3-year OS probability was 26.7% among trial-eligible patients and 9.5% among trial-ineligible patients. Three-year OS was achieved by 22.7% of trial-eligible patients and 6.7% of trial-ineligible patients (P = .003).
“Our study provides the first documentation of the long-term outcomes following chemoimmunotherapy in a large prospective real-world cohort of patients with ES-SCLC,” concluded Dr Sugisaka et al. “These findings provide valuable insights into the practical effectiveness of chemoimmunotherapy and clinical decision-making for patients with ES-SCLC.”
Source:
Sugisaka J, Fujimoto D, Tamiya M, et al. Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study. Lung Cancer. Published online: December 8, 2024. doi: 10.1016/j.lungcan.2024.108056
